Search results
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 2 days agoSECTORFOCUS BLOG A second failure of a late-stage trial testing a gene therapy to treat Duchenne ...
Bill headed to Pritzker's desk will screen babies for Duchenne muscular dystrophy
Chicago Sun-Times· 22 hours agoMy wife and I could’ve never guessed a blood test would send our world crashing into a fatal...
Study finds LED therapy and antioxidant drug benefit muscle regeneration in Duchenne muscular ...
Medical Xpress· 1 day agoAs reported in an article published in the journal PLOS ONE, the strategy prevented muscle...
Sarepta’s stock gains after Pfizer’s Duchenne trial failure - Boston Business Journal
The Business Journals· 2 days agoSarepta Therapeutics, a Cambridge drugmaker known for its Duchenne muscular dystrophy treatments,...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with ...
Morningstar· 3 days ago(NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene ...
Pfizer's Duchenne Muscular Dystrophy Treatment Misses Endpoints
Morningstar· 3 days agoPfizer's gene therapy being developed to treat Duchenne muscular dystrophy missed its primary endpoint in a late-stage trial. The pharmaceutical ...
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
Zacks via Yahoo Finance· 1 day agoPfizer’s PFE phase III study of investigational gene therapy, fordadistrogene movaparvovec, for...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 2 days agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Pfizer’s Phase III DMD gene therapy trial misses primary endpoint
Clinical Trials Arena via Yahoo Finance· 2 days agoPfizer has reported that its Phase III CIFFREO clinical trial of investigational mini-dystrophin...
Pfizer gene therapy for Duchenne fails to meet goals of key trial
BioPharma Dive via Yahoo Finance· 3 days agoThe negative results from the Phase 3 study, called Ciffreo, come a little more than a month after...